Alexion Pharmaceuticals Rating Reiterated by Zacks (ALXN)
Alexion Pharmaceuticals (NASDAQ:ALXN)‘s stock had its “neutral” rating reiterated by Zacks in a research note issued to investors on Friday. They currently have a $176.00 price objective on the stock. Zacks‘s target price suggests a potential upside of 5.36% from the stock’s previous close.
Zacks’ analyst wrote, “Alexion’s second-quarter 2014 earnings of $0.99 per share were in line with the Zacks Consensus Estimate. Increased costs led to modest results. Earnings were however above the year-ago figure by 53%. The company’s revenues jumped 38% in the quarter to $512.5 million. The company upped its earnings guidance to the range of $4.95 to $5.05 per share. Revenues for 2014 are expected in the range of $2.18 billion to $2.20 billion (old guidance: $2.15 billion to $2.17 billion). Growth at Alexion is expected to be driven by strong Soliris sales. Alexion expects several product approvals in the coming years. Successful development and commercialization of these candidates will reduce the company’s dependence on Soliris for growth. We remain Neutral on the stock.”
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded down 0.26% on Friday, hitting $167.04. The stock had a trading volume of 1,176,719 shares. Alexion Pharmaceuticals has a 52-week low of $100.89 and a 52-week high of $185.43. The stock’s 50-day moving average is $162.9 and its 200-day moving average is $159.6. The company has a market cap of $33.040 billion and a price-to-earnings ratio of 101.26.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings data on Thursday, July 24th. The company reported $1.12 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.07 by $0.05. The company had revenue of $512.50 million for the quarter, compared to the consensus estimate of $509.54 million. During the same quarter in the prior year, the company posted $0.73 earnings per share. The company’s quarterly revenue was up 38.5% on a year-over-year basis. Analysts expect that Alexion Pharmaceuticals will post $4.94 EPS for the current fiscal year.
Separately, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Alexion Pharmaceuticals in a research note on Friday, May 9th. They now have a $210.00 price target on the stock, up previously from $200.00. Five research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $183.00.
Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.